Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis

• Published in: Journal of the American Society of Nephrology Vol. 29; no. 7; pp. 2015 - 2027
• Main Authors: Marthi, Amarnath, Donovan, Killian, Haynes, Richard, Wheeler, David C., Baigent, Colin, Rooney, Christopher M., Landray, Martin J., Moe, Sharon M., Yang, Jun, Holland, Lisa, di Giuseppe, Romina, Bouma-de Krijger, Annet, Mihaylova, Borislava, Herrington, William G.
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.07.2018
• Subjects: Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - mortality; Fibroblast Growth Factor-23; Fibroblast Growth Factors - blood; Heart Failure - epidemiology; Humans; Meta-Analysis; Mortality; Myocardial Infarction - epidemiology; Renal Dialysis; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - therapy; Stroke - epidemiology; dialysis; cardiovascular disease; heart failure; chronic kidney disease; fibroblast; FGF23

Background Fibroblast growth factor-23 (FGF-23) has been hypothesized to play a role in the increased risk of cardiovascular disease in patients with CKD. Methods We identified prospective studies reporting associations between FGF-23 concentration and risk of cardiovascular events. Maximally adjust...